Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market ...

Altimmune (ALT – Research Report) received a Hold rating and price target from William Blair analyst Andy Hsieh today. The company’s shares ...

Ratings for Altimmune (NASDAQ:ALT) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ...

Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT stock is a Buy.

Fintel reports that on February 28, 2025, William Blair initiated coverage of Altimmune (NasdaqGM:ALT) with a Market Perform ...

Altimmune is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual ...

NASDAQ:ALT opened at $6.65 on Friday. Altimmune has a 1-year low of $5.28 and a 1-year high of $14.05. The business’s 50-day moving average price is $6.85 and its two-hundred day moving average ...

Top-line data from Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) to be reported in Q2 2025 Investigational New Drug (IND) applications in two ...

Good day, ladies and gentlemen, and welcome to Altimmune fourth quarter and full year 2024 financial results conference call. As a reminder, this call is being recorded. (Operator Instructions) I ...

Earnings per share (EPS) was mostly in line with analyst estimates. Looking ahead, revenue is forecast to grow 66% p.a. on ...

Altimmune, Inc. (NASDAQ:ALT – Free Report) – Stock analysts at B. Riley increased their FY2025 earnings estimates for Altimmune in a research note issued on Friday, February 28th. B.

GAITHERSBURG, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and full ...